PT  - JOURNAL ARTICLE
AU  - Abassi, Mahsa
AU  - Bangdiwala, Ananta S
AU  - Nuwagira, Edwin
AU  - Tadeo, Kiiza Kandole
AU  - Okirwoth, Michael
AU  - Williams, Darlisha A
AU  - Mpoza, Edward
AU  - Tugume, Lillian
AU  - Ssebambulidde, Kenneth
AU  - Hullsiek, Kathy Huppler
AU  - Musubire, Abdu K
AU  - Muzoora, Conrad
AU  - Rhein, Joshua
AU  - Meya, David B
AU  - Boulware, David R
AU  - ,
TI  - Cerebrospinal Fluid Lactate as a Prognostic Marker of Disease Severity and Mortality in Cryptococcal Meningitis
AID  - 10.1101/2020.08.24.20181289
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.08.24.20181289
4099  - http://medrxiv.org/content/early/2020/08/31/2020.08.24.20181289.short
4100  - http://medrxiv.org/content/early/2020/08/31/2020.08.24.20181289.full
AB  - Background Cerebrospinal fluid (CSF) lactate levels can differentiate between bacterial and viral meningitis. We measured CSF lactate in individuals with cryptococcal meningitis to determine its clinical significance.Methods We measured point-of-care CSF lactate at the bedside of 319 HIV-infected Ugandan adults at diagnosis of cryptococcal meningitis. We summarized demographic variables and clinical characteristics by CSF lactate tertiles. We evaluated the association of CSF lactate with clinical characteristics and survival.Results Individuals with high CSF lactate >5 mmol/L at cryptococcal diagnosis more likely presented with altered mental status (p<.0001), seizures (p=.0005), elevated intracranial opening pressure (p=.03), higher CSF white cells (p=0.007), and lower CSF glucose (p=.0003) compared to those with mid-range (3.1 to 5 mmol/L) or low (≤3 mmol/L) CSF lactate levels. Two-week mortality was higher among individuals with high baseline CSF lactate >5 mmol/L (35%; 38/109) as compared to individuals with mid-range (22%; 25/112) or low CSF lactate (9%; 9/97; p=<.0001). After multivariate adjustment, CSF lactate >5mmol/L remained independently associated with excess mortality (adjusted Hazard Ratio = 3.41; 95%CI, 1.55-7.51; p=.002). We found no correlation between baseline CSF lactate levels and blood capillary lactate levels (p=.72).Conclusions Baseline point-of-care CSF lactate levels may be utilized as a prognostic marker of disease severity and mortality in cryptococcal meningitis. Individuals with an elevated baseline CSF lactate are more likely to present with altered mental status, seizures, elevated CSF opening pressures, and are at a greater risk of death. Future studies are needed to determine targeted therapeutic management strategy in persons with high CSF lactate.Summary In HIV-associated cryptococcal meningitis, baseline cerebrospinal fluid (CSF) lactate levels are associated with increased intracranial pressures, seizures, and altered mental status. Elevated CSF lactate levels, at baseline, are associated with increased 2-week mortality.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the U.S. Fogarty International Center (K01TW010268, R25TW009345); National Institute of Neurologic Diseases and Stroke (R01NS086312); National Institute of Allergy and Infectious Diseases (T32AI055433); and the United Kingdom Medical Research Council / Wellcome Trust/ Department for International Development (MRC MR/M007413/1). DBM was also supported by DELTAS Africa Initiative (grant number DEL15011) to THRiVE2. The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences Alliance for Accelerating Excellence in Science in Africa and supported by the New Partnership for Africas Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust (grant number 107742/Z/15/Z) and the UK Government. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All research activities were approved by the University of Minnesota as well as the Ugandan IRB, Uganda National Council for Science & Technology, and the Ugandan National Drug Authority.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data will be made available upon request.